FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: December 31, 2014 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person * Deep Track Biotechnology Master Fund, Ltd. (Last) (First) (Middle) C/O WALKERS CORPORATE LIMITED 190 ELGIN AVE (Street) GEORGE TOWN CT KY1-9001 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/04/2026	3. Issuer Name and Ticker or Trading Symbol Attovia Therapeutics, Inc. [ ATTO ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Redeemable Convertible Preferred Stock	(1)	(1)	Common Stock	1,957,138	(1)	D (2)

Explanation of Responses:

1. Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") is convertible at any time at the option of the holder and will automatically convert into shares of the Issuer's common stock ("Common Stock") upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock has no expiration date.

2. Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests..

	Deep Track Biotechnology Master Fund, Ltd. /s/ David Kroin, Director	08/04/2026
	** Signature of Reporting Person	Date
	Deep Track Capital, LP /s/ David Kroin, Managing Member of the General Partner of the Investment Adviser	08/04/2026
	** Signature of Reporting Person	Date
	/s/ David Kroin	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.